Sanofi-aventis and Avila to Develop Targeted Covalent Oncology Drugs
Avila Therapeutics, Inc. (Waltham, MA) and France-based sanofi-aventis have signed a global alliance to discover targeted covalent drugs for the treatment of cancers. Under the alliance agreement, sanofi-aventis obtains a worldwide exclusive license to develop and commercialize the compounds resulting from the discovery collaboration.
Avila Therapeutics, Inc. (Waltham, MA) and France-based sanofi-aventis have signed a global alliance to discover targeted covalent drugs for the treatment of cancers. Under the alliance agreement, sanofi-aventis obtains a worldwide exclusive license to develop and commercialize the compounds resulting from the discovery collaboration.
As part of the research alliance, sanofi-aventis and Avila will collaborate to design targeted covalent drugs directed toward six signaling proteins that are critical in tumor cells. The targets to be explored under the collaboration are difficult to approach with traditional pharmaceutical treatments, but are potentially amenable to Avila’s targeted covalent drug technology.
Under the terms of the agreement, for the selected targets sanofi-aventis will have access to Avila’s proprietary Avilomics platform that offers an approach to “protein silencing” that cannot be achieved through traditional medicinal chemistry.
Avila has the opportunity to retain the rights to one of the six collaboration programs after the end of the initial three-year collaboration term and sanofi-aventis retains a right of first negotiation for such program, should Avila decide to partner that program.
Avila will receive up to $40 million in upfront and research support payments and is eligible to receive preclinical, clinical, regulatory milestone payments up to $154 million per collaboration program, if the respective product is approved in the US, Europe, and Japan. Avila may also receive staged royalties and commercial milestones on product sales in each of the programs advanced by sanofi-aventis.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Mastering Antibody-Drug Conjugates: BIOVECTRA's Approach to ADC and Complex Chemistry Manufacturing
December 19th 2024BioPharm International sat down with Jean-François Vincent-Rocan, Director of Complex Chemistry Process Development at BIOVECTRA, to discuss antibody-drug conjugate (ADC) manufacturing. Due to their complex manufacture and supply chain management, JF emphasizes the need for a company that greatly understands the challenges and offers solutions that maintain quality and reliability. He also mentions what advancements are to come in this field and how best to stay ahead of a rapidly growing treatment option.
